메뉴 건너뛰기




Volumn 9, Issue 3, 2015, Pages 261-267

Management of bone metastases in prostate cancer: A review

Author keywords

Bone metastasis; Denosumab; Prostate Cancer; Radium 223; zoledronic acid

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; DENOSUMAB; IMIDAZOLE DERIVATIVE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIUM; RADIUM CHLORIDE RA 223; ZOLEDRONIC ACID;

EID: 84942909317     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000157     Document Type: Review
Times cited : (29)

References (35)
  • 1
    • 84942860119 scopus 로고    scopus 로고
    • How i treat patients with bone metastases
    • Lipton A. How I treat patients with bone metastases. Oncology Times 2013; 35:32-34.
    • (2013) Oncology Times , vol.35 , pp. 32-34
    • Lipton, A.1
  • 2
    • 84867582660 scopus 로고    scopus 로고
    • Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
    • Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012;48:3082-3092.
    • (2012) Eur J Cancer , vol.48 , pp. 3082-3092
    • Lipton, A.1    Fizazi, K.2    Stopeck, A.T.3
  • 3
    • 84875074661 scopus 로고    scopus 로고
    • Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice
    • So A, Chin J, Fleshner N, Saad F. Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice. Can Urol Assoc J 2012; 6:465-470.
    • (2012) Can Urol Assoc J , vol.6 , pp. 465-470
    • So, A.1    Chin, J.2    Fleshner, N.3    Saad, F.4
  • 4
    • 84890603325 scopus 로고    scopus 로고
    • Bone-targeted therapies in metastatic castration-resistant prostate cancer: Evolving paradigms
    • El-Amm J, Freeman A, Patel N, Aragon-Ching JB. Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. Prostate Cancer 2013; 2013:210686.
    • (2013) Prostate Cancer , vol.2013 , pp. 210686
    • El-Amm, J.1    Freeman, A.2    Patel, N.3    Aragon-Ching, J.B.4
  • 5
    • 84872507131 scopus 로고    scopus 로고
    • Radium-223 chloride: A potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease
    • Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res 2013; 5:1-14.
    • (2013) Cancer Manag Res , vol.5 , pp. 1-14
    • Harrison, M.R.1    Wong, T.Z.2    Armstrong, A.J.3    George, D.J.4
  • 6
    • 84884777163 scopus 로고    scopus 로고
    • Radium-223 (alpharadin) a novel targeted alpha-emitter for bone-metastatic castrate-resistant prostate cancer
    • Sartor O. Radium-223 (alpharadin) a novel targeted alpha-emitter for bone-metastatic castrate-resistant prostate cancer. PCRI Insights 2012; 9-15.
    • (2012) PCRI Insights , pp. 9-15
    • Sartor, O.1
  • 7
    • 5444242637 scopus 로고    scopus 로고
    • Bisphosphonates: Preclinical review
    • Green JR. Bisphosphonates: preclinical review. Oncologist 2004; 9 (Suppl 4): 3-13.
    • (2004) Oncologist , vol.9 , pp. 3-13
    • Green, J.R.1
  • 8
    • 84871918834 scopus 로고    scopus 로고
    • New and emerging therapies for bone metastases in genitourinary cancers
    • Saylor PJ, Armstrong AJ, Fizazi K, et al. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol 2013; 63:309-320.
    • (2013) Eur Urol , vol.63 , pp. 309-320
    • Saylor, P.J.1    Armstrong, A.J.2    Fizazi, K.3
  • 9
    • 20644447798 scopus 로고    scopus 로고
    • First clinical experience with a-emitting radium-223 in the treatment of skeletal metastases
    • Sten Nilsson RHL, Fossa Sophie D, et al. First clinical experience with a-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005; 11:4451-4459.
    • (2005) Clin Cancer Res , vol.11 , pp. 4451-4459
    • Nilsson RHL, S.1    Fossa Sophie, D.2
  • 10
    • 84873864130 scopus 로고    scopus 로고
    • Bone-tarageting radiopharmaceuticals including radium-223
    • Darren Brady CCP, O'Sullivan Joe M. Bone-tarageting radiopharmaceuticals including radium-223. Cancer J 2013; 19:71-78.
    • (2013) Cancer J , vol.19 , pp. 71-78
    • Brady CCP, D.1    O'Sullivan Joe, M.2
  • 11
    • 84881630281 scopus 로고    scopus 로고
    • Phase i pharmaco-kinetic and biodistribution study with escalating doses of (2)(2)(3)Ra-dichlor-ide in men with castration-resistant metastatic prostate cancer
    • Carrasquillo JA, O'Donoghue JA, Pandit-Taskar N, et al. Phase I pharmaco-kinetic and biodistribution study with escalating doses of (2)(2)(3)Ra-dichlor-ide in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2013; 40:1384-1393.
    • (2013) Eur J Nucl Med Mol Imaging , vol.40 , pp. 1384-1393
    • Carrasquillo, J.A.1    O'Donoghue, J.A.2    Pandit-Taskar, N.3
  • 12
    • 2942518111 scopus 로고    scopus 로고
    • Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
    • Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96:879-882.
    • (2004) J Natl Cancer Inst , vol.96 , pp. 879-882
    • Saad, F.1    Gleason, D.M.2    Murray, R.3
  • 13
    • 0037009822 scopus 로고    scopus 로고
    • A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
    • Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
    • (2002) J Natl Cancer Inst , vol.94 , pp. 1458-1468
    • Saad, F.1    Gleason, D.M.2    Murray, R.3
  • 14
    • 78149356666 scopus 로고    scopus 로고
    • Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer
    • Saad F, Eastham J. Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology 2010; 76:1175-1181.
    • (2010) Urology , vol.76 , pp. 1175-1181
    • Saad, F.1    Eastham, J.2
  • 15
    • 84901944163 scopus 로고    scopus 로고
    • Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (alliance)
    • Smith MR, Halabi S, Ryan CJ, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 2014; 32:1143-1150.
    • (2014) J Clin Oncol , vol.32 , pp. 1143-1150
    • Smith, M.R.1    Halabi, S.2    Ryan, C.J.3
  • 16
    • 69049105440 scopus 로고    scopus 로고
    • Denosumab in men receiving androgen-deprivation therapy for prostate cancer
    • Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361:745-755.
    • (2009) N Engl J Med , vol.361 , pp. 745-755
    • Smith, M.R.1    Egerdie, B.2    Hernandez Toriz, N.3
  • 17
    • 84855516339 scopus 로고    scopus 로고
    • Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial
    • Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 39-46.
    • (2012) Lancet , vol.379 , pp. 39-46
    • Smith, M.R.1    Saad, F.2    Coleman, R.3
  • 18
    • 79551568488 scopus 로고    scopus 로고
    • Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study
    • Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132-5139.
    • (2010) J Clin Oncol , vol.28 , pp. 5132-5139
    • Stopeck, A.T.1    Lipton, A.2    Body, J.J.3
  • 19
    • 79952360832 scopus 로고    scopus 로고
    • Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study
    • Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-822.
    • (2011) Lancet , vol.377 , pp. 813-822
    • Fizazi, K.1    Carducci, M.2    Smith, M.3
  • 20
    • 79952761418 scopus 로고    scopus 로고
    • Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
    • Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29:1125-1132.
    • (2011) J Clin Oncol , vol.29 , pp. 1125-1132
    • Henry, D.H.1    Costa, L.2    Goldwasser, F.3
  • 21
    • 84858706749 scopus 로고    scopus 로고
    • A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
    • Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012; 48:678-686.
    • (2012) Eur J Cancer , vol.48 , pp. 678-686
    • Nilsson, S.1    Strang, P.2    Aksnes, A.K.3
  • 22
    • 84874543674 scopus 로고    scopus 로고
    • Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone me-tastases
    • Nilsson S, Franzen L, Parker C, et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone me-tastases. Clin Genitourin Cancer 2013; 11:20-26.
    • (2013) Clin Genitourin Cancer , vol.11 , pp. 20-26
    • Nilsson, S.1    Franzen, L.2    Parker, C.3
  • 23
    • 84874543674 scopus 로고    scopus 로고
    • Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases
    • Nilsson S, Franzén L, Parker C, et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase ii study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer 2013; 11:20-26.
    • (2013) Clin Genitourin Cancer , vol.11 , pp. 20-26
    • Nilsson, S.1    Franzén, L.2    Parker, C.3
  • 24
    • 84880428467 scopus 로고    scopus 로고
    • Alpha emitter radium-223 and survival in metastatic prostate cancer
    • Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369:213-223.
    • (2013) N Engl J Med , vol.369 , pp. 213-223
    • Parker, C.1    Nilsson, S.2    Heinrich, D.3
  • 26
    • 5444243800 scopus 로고    scopus 로고
    • Safety of intravenous and oral bisphosphonates and compliance with dosing regimens
    • Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004; 9 (Suppl 4):28-37.
    • (2004) Oncologist , vol.9 , pp. 28-37
    • Conte, P.1    Guarneri, V.2
  • 27
    • 84891437622 scopus 로고    scopus 로고
    • Zoledronic Acid-Cancer Care Ontario
    • Zoledronic Acid-Cancer Care Ontario https://www.cancercare.on.ca/2013. Drug Monograph.
    • (2013) Drug Monograph
  • 28
    • 84860467736 scopus 로고    scopus 로고
    • Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
    • Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23:1341-1347.
    • (2012) Ann Oncol , vol.23 , pp. 1341-1347
    • Saad, F.1    Brown, J.E.2    Van Poznak, C.3
  • 29
    • 84860467736 scopus 로고    scopus 로고
    • Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
    • Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23:1341-1347.
    • (2012) Ann Oncol , vol.23 , pp. 1341-1347
    • Saad, F.1    Brown, J.E.2    Van Poznak, C.3
  • 30
    • 84888188544 scopus 로고    scopus 로고
    • Robot assistedradical prostatectomy:how i do it. Part I: Patient preparation and positioning
    • Valdivieso RF, Hueber PA, Zorn KC. Robot assistedradical prostatectomy:how I do it. Part I: Patient preparation and positioning. Can J Urol 2013; 20:6957-6961.
    • (2013) Can J Urol , vol.20 , pp. 6957-6961
    • Valdivieso, R.F.1    Hueber, P.A.2    Zorn, K.C.3
  • 31
    • 33544469496 scopus 로고    scopus 로고
    • The significance of key regulators of apoptosis in the development and prognosis of prostate carcinoma. II. Products of suppressor genes Rband PTEN, CDKI, Fas. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc
    • Knillova J, Kolar Z, Hlobilkova A. The significance of key regulators of apoptosis in the development and prognosis of prostate carcinoma. II. Products of suppressor genes Rband PTEN, CDKI, Fas. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc. Czechoslovakia 2003;147:11-17.
    • (2003) Czechoslovakia , vol.147 , pp. 11-17
    • Knillova, J.1    Kolar, Z.2    Hlobilkova, A.3
  • 32
    • 34347244905 scopus 로고    scopus 로고
    • Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study
    • Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8:587-594.
    • (2007) Lancet Oncol , vol.8 , pp. 587-594
    • Nilsson, S.1    Franzen, L.2    Parker, C.3
  • 33
    • 20644447798 scopus 로고    scopus 로고
    • First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases
    • Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005; 11:4451-4459.
    • (2005) Clin Cancer Res , vol.11 , pp. 4451-4459
    • Nilsson, S.1    Larsen, R.H.2    Fossa, S.D.3
  • 34
    • 84871926771 scopus 로고    scopus 로고
    • A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (ra 223) in patients with bone metastases and castration-resistant prostate cancer
    • Parker CC, Pascoe S, Chodacki A, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 2013; 63:189-197.
    • (2013) Eur Urol , vol.63 , pp. 189-197
    • Parker, C.C.1    Pascoe, S.2    Chodacki, A.3
  • 35
    • 30944461586 scopus 로고    scopus 로고
    • PTEN and GSK3beta: Key regulators of progression to androgen-independent prostate cancer
    • Mulholland DJ, Dedhar S, Wu H, Nelson CC. PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer. Onco-gene 2006; 25:329-337.
    • (2006) Onco-gene , vol.25 , pp. 329-337
    • Mulholland, D.J.1    Dedhar, S.2    Wu, H.3    Nelson, C.C.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.